

the specification. Applicants note that the nucleotide sequences on page 24, lines 25 and 26, were not recited in the Sequence Listing since only sequences of 10 or more bases need to be recited.

Specification pages 16 and 39 were amended to include SEQ ID NOs in order to correlate the sequences discussed in the specification with the sequences listed in the Sequence Listing. Marked-up and clean copies of each of the amended paragraphs are included herewith.

Applicants respectfully request timely examination of the above-referenced application.

Respectfully submitted,

**ROCIO SIERRA-HONIGMANN *et al.***

October 7, 2001  
(Date)

By: Kathryn Doyle  
KATHRYN DOYLE, Ph.D, J.D.  
Registration No. 36,317  
MORGAN, LEWIS & BOCKIUS, LLP  
1701 Market Street  
Philadelphia, PA 19103-2921  
Telephone: (215) 963-5000  
Direct Dial: (215) 963-4723  
Facsimile: (215) 963-5299  
E-Mail: [kdoyle@morganlewis.com](mailto:kdoyle@morganlewis.com)  
Attorney for Applicants

KD/GHL

Enclosures: Sequence Listing in Paper and Computer Readable Format  
Statement to Support Sequence Listing  
Copy of the Notification of Missing Requirements  
Marked-up and clean copies of amended paragraphs

**Marked-up Copy of Amended Paragraphs**

Page 16, lines 14-25:

The present inventor contemplates using leptin and other agents that modulate the leptin receptor as a means of modulating angiogenesis, wound healing and/or repair of ischemic tissue. Correspondingly, agents contemplated include leptin, the leptin receptor, other leptin receptor ligands, allelic variants of leptin and the leptin receptor, and corresponding proteins in which conservative amino acid substitutions have been made such as fusion proteins. Examples of such leptin and leptin receptor nucleic acid molecules and corresponding protein sequences are disclosed as follows: GenBank Accession Nos. U58861 (*Mus musculus*; SEQ ID NOs:1 and 2), D49653 (*Rattus norvegicus* leptin; SEQ ID NOs:3 and 4), U52966 and U60151 (*Rattus norvegicus* Ob-Rb; SEQ ID NOs:5-8), U43168 (human Ob-R; SEQ ID NOs:9 and 10), U59894 (*Sus scrofa* leptin; SEQ ID NOs:11 and 12), AF039461 (*Mus musculus* leptin receptor isoform Rb; SEQ ID NOs:13 and 14), and U50365 (*Bos taurus* leptin; SEQ ID NOs:15 and 16). Other leptin and leptin receptor sequences are readily determinable and available to the skilled artisan.

Page 39, lines 13-26:

Peptide antibodies were based on the sequence of the human leptin receptor (G. H. Lee *et al.*, (1996) Nature 379:632) corresponding to regions within the intracellular or the extracellular domain. These peptides were synthesized and coupled to KLH. The intracellular region peptides were (1) IC-1 for residues 1148-65 at the carboxy terminal end of the receptor (CSTQTHKIMENKMCDLTV; SEQ ID NO:17), and (2) IC-2, for residues 1062-1078 (KLEGNFPEENNDKKSIV; SEQ ID NO:18). The extracellular region peptides were (1) EC-1, for residues 247-263 (ITDDGNLKISWSSPLV; SEQ ID NO:19), (2) EC-2, for residues 473-487 (CSDIPSIHPISEPKD; SEQ ID NO:20), and (3) EC-3, for residues 753-67 (CVIVSWILSPSDYKL; SEQ ID NO:21). The KLH-peptide conjugates were used to generate polyclonal antibodies in rabbits, and IgG fractions prepared from bleeds with the highest ELISA titers. Unless indicated otherwise, antibodies against IC-1 and IC-2 were combined in equal amounts giving rise to  $\alpha$ OB-R<sub>ext</sub> antibodies directed against extracellular eptiopes of the OB-R.

### Clean Copy of Amended Paragraphs

Page 16, lines 14-25:

The present inventor contemplates using leptin and other agents that modulate the leptin receptor as a means of modulating angiogenesis, wound healing and/or repair of ischemic tissue. Correspondingly, agents contemplated include leptin, the leptin receptor, other leptin receptor ligands, allelic variants of leptin and the leptin receptor, and corresponding proteins in which conservative amino acid substitutions have been made such as fusion proteins. Examples of such leptin and leptin receptor nucleic acid molecules and corresponding protein sequences are disclosed as follows: GenBank Accession Nos. U58861 (*Mus musculus*; SEQ ID NOs:1 and 2), D49653 (*Rattus norvegicus* leptin; SEQ ID NOs:3 and 4), U52966 and U60151 (*Rattus norvegicus* Ob-Rb; SEQ ID NOs:5-8), U43168 (human Ob-R; SEQ ID NOs:9 and 10), U59894 (*Sus scrofa* leptin; SEQ ID NOs:11 and 12), AF039461 (*Mus musculus* leptin receptor isoform Rb; SEQ ID NOs:13 and 14), and U50365 (*Bos taurus* leptin; SEQ ID NOs:15 and 16). Other leptin and leptin receptor sequences are readily determinable and available to the skilled artisan.

Page 39, lines 13-26:

Peptide antibodies were based on the sequence of the human leptin receptor (G. H. Lee *et al.*, (1996) Nature 379:632) corresponding to regions within the intracellular or the extracellular domain. These peptides were synthesized and coupled to KLH. The intracellular region peptides were (1) IC-1 for residues 1148-65 at the carboxy terminal end of the receptor (CSTQTHKIMENKMCDLTV; SEQ ID NO:17), and (2) IC-2, for residues 1062-1078 (KLEGNFPEENNDKCSIY; SEQ ID NO:18). The extracellular region peptides were (1) EC-1, for residues 247-263 (ITDDGNLKISWSSPPLV; SEQ ID NO:19), (2) EC-2, for residues 473-487 (CSDIPSIHPISEPKD; SEQ ID NO:20), and (3) EC-3, for residues 753-67 (CVIVSWILSPSDYKL; SEQ ID NO:21). The KLH-peptide conjugates were used to generate polyclonal antibodies in rabbits, and IgG fractions prepared from bleeds with the highest ELISA titers. Unless indicated otherwise, antibodies against IC-1 and IC-2 were combined in equal amounts giving rise to  $\alpha$ OB-R<sub>ext</sub> antibodies directed against extracellular eptiopes of the OB-R.